Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma
2025 · Scientific Reports · 3 citations
https://doi.org/10.1038/s41598-025-09806-1
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
18
Papers
50
Citations
4
h-index
1
i10-index
Takafumi Fukushima is an academic researcher from Hiroshima University. The author has contributed to research in topics: Renal cell carcinoma treatment & Bladder and Urothelial Cancer Treatments & Prostate Cancer Treatment and Research. The author has an h-index of 4, co-authored 16 publications.
ORCID: 0009-0007-4434-2319https://doi.org/10.1038/s41598-025-09806-1
https://doi.org/10.1038/s41598-024-55448-0
https://doi.org/10.1038/s41598-025-22561-7
Click to start Chat